Abstract
Immune checkpoint inhibitors (ICIs) added to first-line small cell lung cancer (SCLC) management increases the importance of understanding baseline factors/treatment contributing to long-term survival. While reported ICI trials have focused on extensive stage disease, active trials investigate possible benefits of adding ICIs in the treatment of limited stage (LS) SCLC. Here we examine factors associated with real-world long-term survival in LS-SCLC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
